(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 10.54% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Ani Pharmaceuticals's revenue in 2025 is $674,068,000.On average, 1 Wall Street analysts forecast ANIP's revenue for 2025 to be $17,154,086,327, with the lowest ANIP revenue forecast at $17,154,086,327, and the highest ANIP revenue forecast at $17,154,086,327. On average, 7 Wall Street analysts forecast ANIP's revenue for 2026 to be $18,438,747,382, with the lowest ANIP revenue forecast at $17,771,451,474, and the highest ANIP revenue forecast at $19,097,161,896.
In 2027, ANIP is forecast to generate $19,722,801,903 in revenue, with the lowest revenue forecast at $18,364,988,493 and the highest revenue forecast at $20,643,824,055.